Faeth nets $25M to push PIKTOR Phase 2

Faeth Therapeutics has closed a strategic financing that injects $25 million into its PIKTOR program, pushing the regimen into a randomized Phase 2 study after an impressive early signal in endometrial cancer. The new round lifts total capital raised to about $92 million and coincides with a late-breaking presentation of PIKTOR data at the upcoming ESMO congress.

The company's Phase 1b combination — pairing selective PI3K and mTOR inhibitors with standard chemotherapy — produced a striking 80% objective response rate in patients with advanced endometrial cancer, and a median progression-free survival of roughly 11 months. Those outcomes compare favourably to historical single-agent chemotherapy benchmarks of approximately 3–4 months and help explain why the Gynecologic Oncology Group Foundation launched a randomized Phase 2 (GOG-3111, NCT06463028) that is now recruiting.

Faeth argues the biology explains the effect: rather than blocking a single node in the PI3K/AKT/mTOR cascade, PIKTOR aims at multiple pathway nodes while also restricting the metabolic fuels tumours exploit. The company’s MetabOS™ platform integrates genomic and microenvironment data to pinpoint metabolic dependencies; preclinical work suggests combined pathway blockade plus nutrient restriction produces deeper pathway shutdown than monotherapy approaches.

From an investor angle, the round drew both existing backers and new money. Lead participation came from S2G Investments, with follow-on support from firms including Khosla Ventures, B Capital, Future Ventures, Digitalis Ventures, KdT Ventures, Cantos, Avicella and THO Seed Fund. In public comments, S2G Managing Partner Sanjeev Krishnan framed the deal as part of a wider trend: investors are allocating to metabolism-directed oncology strategies as clinical evidence accumulates for multi-node targeting.

CEO Anand Parikh described the financing as the capital needed to complete a full Phase 2 readout targeted for Q3 2026 and to scale MetabOS throughput. The company also plans to advance a nutrient-restriction program into a Phase 1 rectal cancer trial and to move a non-oncology program for Hereditary Tyrosinemia Type 1 (HT1) through IND-enabling work, with potential clinical entry in late 2026.

For investors and industry watchers, Faeth’s progress highlights two linked themes. First, the PI3K/AKT/mTOR axis remains one of the most commonly altered signalling networks across solid tumours — targeting it at multiple nodes can overcome feedback loops that blunt single-agent durability. Second, metabolic intervention is emerging as a complementary modality to genomics and immunotherapy, attracting capital as companies translate mechanistic insights into clinic-ready regimens.